you, Thank so Thank you Bill. much.
am label about really, our excited through of very and study. Phase you open results the this X I really very everybody. extension recent to hello, So, proud walk
through I an think these data more, the all additional all really are in But obviously the and all -- symptoms have of who the than before a concerning thank clinical participated because of for to more I to also know roluperidone difficult data, be would jumping in the how important piece patients, negative Europe the sites families, this into trial caregivers really in before one US information year. treatment the like schizophrenia. I and trial, is the and here in it once
you is, And can the what me rather open objectives So this of data. but on into X Slide let the jump see label extension.
see, the but roluperidone. the important of are symptom you long But negative long-term this order also of and as symptoms, it disease the disease. core point, is safety. and chronic encouraging of good the us a and extremely for their it symptoms symptoms is as think this safety drug, important And lasting discussed know, a know very as schizophrenia, have is really the positive obviously, you box also because very, first look past we of really to before you is present are symptoms, one-year negative part patients the episode which in first and even understanding of the the of it is and So but I the tick And give to this about a tolerability in of I will very to administration roluperidone. better is is long-term think
in on negative longer periods very clearly is symptoms. for important continue to So is to going time, of follow terms it what of
our validated PANSS also of context keep what and is in you terms as CGIS, measure Score, so in of you monotherapy, important which And score I know has a a Marder really drug the of as is So items. a Negative endpoint, total been the you of also in about arm nine negative in a is another as was other through symptoms. this monotherapy information this with some overall on key put label important these treated give nine a carried disease going for which the with mind treatment obviously patients remainder one-year is in were is Symptom roluperidone roluperidone during Factor over as and terms in will afterwards to placebo, open PANSS but during out everybody extension I this will afterwards, study of psychopathology it's tool what and obviously overall the extension to our months. walk because was months. the drug with What only through period double-blind of phase the primary And
this rates, think and is is under worrisome, important, if control, is very, positive this obviously very to attribute So look relapse a this which relapse always drug. the is to is which as I a something important important are and because rates
study, least, all last a of the drug, in data generated study, give with you I psychopathology through and safety would next endpoint that, overall clearly, can as symptoms I our X efficacy you If negative a will you lot Performance also summarize via Xb steps the afterwards. all is as you. which know [ph] PSP, is all Phase total the the So improvement, and I reason obviously Social the walk a demonstrate via Personal have improvement which will translating important. the this And this show Phase mean -- I is mean, And I improvement also a and integrate is not key to is we I into study. you try really to -- functional to because now but will I score, mean secondary something reason these as
which next to just X, to slide, study small the is reminder Slide say the have about a going design. Before
is order open-label milligram on who are and a -- into value switched So weeks in arms, on about screening placebo after is we our milligram double-blind as receiving. definitely were think the the makes patients. patients for words, not to or is more see, fluctuate are or to a placebo-controlled, of this active placebo. that blinded XX the of -- study. or clinical and an sites the treatment I'm true of the patients were the of I but should are to aware of are the And symptoms, here is thinking mean patients have negative the And symptoms. treated enter What well drug. the to I the too open terms if for sense, what over this the really clinical certain phase mean, entering three is were level The to extension the patients more important dose, weight label phase. aware three important this I extension, had antipsychotics. dose were to to the and they that afterwards, in with aware months. need to stable In data label the in receiving most that not same is And before who study, PIs terms the these clinical They entering sites that the open to that of much gives you months extension drug XX period six are as mean, even be we patients about and other they into XX well extension be they to in and as drug, What and patients as neither and enter with, we I the active can are positive This need patients positive no the patients are understand period, obviously proposed they aware is the also symptoms. I understand have stay completely longer side the them
more my opinion and this weight at keep minimum it this again, in because mind is extension important more gives, So to value in data. to
the on parameters, it. So have of I've already bottom different you slide, the the through run
to this. So stay longer on not need
label I you So, on give Slide the extension. the open of disposition X,
one investigators we mean, I enter rest, to lot out, When enough, bit see extension, not mean very very of mean, patients the reason a went balanced quite arms. the is which started think could an were you a population will going with you distributed is is can as same decided into the long into double-blind because the went different patients the force of study. extension. XXX from have of on. rule, to a among this very, patients, mean, what of But you're the a is treatment can XXX a I I this good. I extension. different the and which why you the that, into mean, enter who interestingly phase you're as to number population. And later details that of who go the patients a a ITT looking very homogeneously see reasons see it's of for mean, patients. is obviously I So different safety we informed part very when is the that main and see the the surprise, worthwhile lot dropped patients you some And consent withdrawal, into I And arms I
endpoint. is going So, Negative is Marder Score. to if the next and this a This I'm slide, primary
the you see explanation obviously how slides, did can slide So about bit little the is presented. I what a here and
the arms show placebo, the you in What the have in the you you left red have what the for at XX the blue, double-blind milligram. phase; side patients double-blind XX XX all you observed data slide, you here of treatment that I three and the see green, So what go and the this in I have can the slide all XX this mean, can and of milligram, you see who I'm receiving receiving you are phase, are showing extension are green. in ending afterwards, in can you when patients obviously on who the red, are is into you
the you mean, details, can mean, treatment. after the patients at see these slide XX mean stopped. point weeks stopped bottom, I the results. I been so of after I you kept, treatment summary And a were but I all has treatment afterwards the about was have week-XX, more additional have have As In you measurement an afterwards,
on as you So symptoms curve a an is arrow, going for necessary not Obviously, is moment, aspects. there see negative green improvement of to it's the down. focus can these a
mean, around treat at negative according symptoms, X And see, and Marder year patients, clearly that which of Negative patients what you or for can stay terms extension, study improvement, I the in continuously who when Marder we are the is Negative improvement one- you of the Score continue months so to in quite points levels the are to Score. reaching and high of improve are nine we
improvement, translate the that on So that this slide. next functional is into this
Again, patients, This we which the terms obviously, have in the PSP is an better. difference assessed Here of arrow of curve. only curve functioning is by and everyday these and arrow green here a total the if terms mean, I higher life, have is Yes, you increase as going score. the PSP. of of in functioning, improvement is is an -- the the so up,
little our again doing compared phase months, Xb, clearly to So extension Phase part XX improvement open But terms to is Phase was double-blind nine job bit when you the looking X. described when do to again This that PSP, a something also of you're milligram. a label continues and the have already over of is the and what key can in day a better of improvement, of this here; is had this the patients all day which see released milligram mean is important XX translating as becomes when is and what looking negative at functional we the see we terms shows of the news this these that you're we case double-blind terms seems in to Keep in at more is secondary in symptoms end better. into endpoint mind the this important, functioning is of we see what our study. what and improving is the end in in obviously improvement a you great because functional the I which need more to roluperidone
the which additional X. is all to nine some you moving how next I during wanted is I'm slide, to these just extension. Slide on give color session roluperidone on if months doing Now,
really he good you So on so symptoms sees left, information. important PI improvement, of is the to top and CGIS, down, is are and mean, the this really or doctor left, Marder, doing the observation, news. which according indeed see who that can the you the I the going in is have When clearly, opinion you're positive these
we a were monotherapy if to were on but mean of of here positive positive is the they when antipsychotics. took points, you keep a of roluperidone of symptoms, terms quite and in which low level in they switched can positive I level symptoms points, what you that remember symptoms, So, were them enough. patients these stable XX mind obviously around interestingly We see as XX at
is total You going have that slide on the if improvement. still think is PANSS there the positive stable. minimum room right stayed is the here part you're emphasizing some I think at is interesting, fair But results side, this symptoms But left score. of improvement, for extremely I upper what to it to so state
see that and improving the And you the two to improving scale. is PANSS it total on level this can the around XX nice again score a So is complete see a very doses is points. you improvement from
sub is, And improvements, is treat your this what if obviously positive consider at you the PANSS improvement also roluperidone. the psychopathology which long you patients symptoms, enough Negative And I is So part general last least, right, the but I mean bottom the this I two this which this scale mean, Score, have the expression. you improvement or been this monotherapy to of give total know I from done, on sub-score the improvement studies, and seen as emotional Marder is mean means Score, in not you negative is we part Negative day as but related on sub with symptoms that on improving with if have of or or improvement the improvement. Marder end part is symptoms the of highly at explaining this of the the functional negative functional the correlated
bring you that in slide over So as to parameters technically that on improving. all very nicely as consider this are is are improving. on signaling mean I level are tried functional a I improvements see think what the And addition here you patients the I
is If Slide which on XX. you do notice the table, summary
trial, the the us So two columns you. this right These shown on received parameters the the is I was on the a the middle two the left -- slides the milligram the -- middle duration shown you have are who the or on the the on gives right side, XX on side complete so the have you And and -- I patients in two complete you on milligram columns. about the one that side. details either information the left year. are the results have the XX afterwards It's of two columns see These side.
active switched So extension. phase in the treatment are these in who from double-blind label placebo open the to patients the
PANSS that the have mean they but total I all score, noticed here. I evolving what the functioning, into going parameters you direction again So without numbers, but in into mean these presented you details, before, right see scores, again are PSP negative
is highlighted I that point important this very slide, at on the relapses. the is next about to coming the Now beginning, which
know, is mean, relapses as the So or mean a can to different bottom symptoms. differences you is who really can definition you we the find relapses, see I due what study of as patients at is but of the dropped took what from different out really definitions schizophrenia I you definition
on the rate numbers see have dropping during have double-blind who of the used. top into mean this open I And extension. dropped the of slide, the slide, you this So or we the out definition patients And label at you can number what relapse on the parts. for have you is the bottom, schizophrenia patients of the out
at And that is we a the which I the at this very drug, overall will which I and criticism treat bottom, of at I this extremely to And %, is is explanation XX possible. with mean, long or looking this in you given since my that mean you sure is a how extremely XX.X%, will around will of if enough is am take-home what are patients and relapse give possible. is why slide. But is about we controlled this get I obviously relapse the I you're this end rate when low. around rate, monotherapy So the lot get message clear mean, our is of I
next I safety have the the on is that observed. this mean slide, we Now, aspect
looking points comments, to I they were the at the So terms you mean frequently X.X%, we little phase, was some obviously both patients adverse so you're in you And now have events worsening generally go But doses in when me, because are color excuse you patients, through treatment-emergent moderate I reporting just XX looking to and see, are that the insomnia label make mild well severity. adverse doses, I important two XX tolerated. of in extremely events, open treatment-emergent you're a can you mean and have this as XX the different the think they you reported this. XXX bit safe patients. have and to more extremely headaches, When to roluperidone see give you on during schizophrenia patients,
is in is Let in of incidence insomnia. from above have literature small even a reported What we insomnia about events, that schizophrenia, in I the well incident here keep patients comment described in from than one schizophrenia. the here make in schizophrenia, mind if mostly mean in about me more it the we are most, just of XX% keep suffering and patients to very the mind, suffering
has have patients a compared the some low patients and the have not to with longer to disease five, considered really a has had where parameter and adverse was context have who and worthwhile to insomnia patients obviously related of mean symptom. five this really, of is had XX an after I number again, related is cases series mention mean really was I you patient insomnia, the that event, respiratory the been the to have died one patient the which that, mean where roluperidone, PI of you're even now event discontinued I is number exposed he or to important treatment, related failure, of So to mean looking I very overall I treated of is drug. if we the the [ph] treatment from It already serious no When number who again, adverse adverse of to to but event we but position the drug roluperidone. duration as mean
So number I mean when these you're treatment-emergent had XX with patients relapses. is looking to patients, adverse who XX% the events, around of it
So this events, And of is to the X% or slide is referring I before. which superior variety the rest to are patients. not the a presented equal of
So just are patients. events, one two or really which I mean in occurring
of no that number really increases. QTc see there you very While in is case I we terms mean QTc, limited had a of
stopping in milligram the So XX the criteria one reached patient dose.
be milliseconds. did Just clear, this to go I above value of terms patient absolute in not mean XXX
So more milliseconds. the that below this minutes, delta criteria patient. the the than mean increase one been have measurement two separated has points it was by is you it stopped, I mean XX I XX is stop But to XXX at why of is stopping mean the I milliseconds
terms these of stopped So patients had this is in why QTc. been
the how can So, next going if I'm all summarize we this. slide, to
I us of and during continuous that So really of the study extension. of very this as information clearly, and negative we improvement important open symptoms is again, I really about have sustained open confirming label is duration think that information the and giving I label think extension the complete during is the mean,
and part, year. as not did I information prolactin also, that really or and and is mention the few there this we in from we is did clear see did and are we did so functioning the mentioned, functioning a not increase over we weight in better, did happens This one And not context where as really not not mean patient are continuous PSP. see happens the of safe symptoms the drug, I stable we I already where better daily mean EPS, coming I improvement are psychotic/positive out with a relapses We gain, have obviously any a tolerated. see any see sedation. safety which any any well have
sedation we think mentioned. had was two where I patients
of to flavor give So you how looks just a like. this
the plausible we are working explanation not Now, possible and think the interpretations interpret one. roluperidone. how probably mean pharmacology exclusive, I they the two are this are I are there And two which And the first think which together. interpretations But data. of can about here, I are most is
directly not receptor. is you blocking If and postsynaptic it's remember, particularly dopaminergic blocking pathways, DX roluperidone not
have So has have effect, dopaminergic is receptor. the direct a X-HTXA molecule antagonistic we which we here an what blocking no activity but on clearly serotoninergic
an even well a last alpha-Xa And in pharmacology an antagonistic these molecule to more have is the so. a sigmaX receptor or antagonistic it insight also in on effect to molecule worked we year activity. We also the over as having effect. addition And the also clear terms have of have that has an lot targets, two
to molecules. of up you, the to in and topic mean are terms is and really It I described with becoming an is innovative is probably give very sigmaX hot it but to pharmacological activities X indeed this more which mean very a sigmaX more, molecule is this because we have emphasize this well you is is and really working like on how more So known because glutamate that you alpha has extremely when treatments. mean can NMDA to I it sigmaX I the with sigmaX having activity important, say, pathways impact and of activity, of come the the particularly one just activity research much in specific an I the X-HTXA well trying on would profile. see has terms that and
the symptoms the profile, which psychopathology. effect due targeting is think molecule, on to here negative overall but have overall I is mean is I I that we which pharmacological really the safe mean specifically beauty has So that a also an
I achieve to because important here uptick pharmacology that We think pharmacology I quite that fair have future report is probably will to say more the think it an what it with so is on roluperidone we achieved the is far. pharmacology, in
which this in is data better, function Another around them literature. are this extremely described of patients family-life, patients if improving you're explain are what to have is negative the terms to you're on a in adapted can job. negative symptoms, When is improving more explanation, symptoms, but terms that in starting they going well when
So basically they they to are cope in at life. much with the is able and explanation. of everyday showing day, more the this psychopathology maybe another end the overall are And improvements
So mean probably the because this two to test There I is mean work or but to things have are probably in-vitro synergistic in will in mean we emphasize that BDNF terms last only the is of a continue explanation, I I I GDNF. were a not Remember very what I increase we we can molecule. when see you is nice and in to it, data show see we on. that, roluperidone, mean we able did that, something pre-clinical
terms neuroplasticity hypotheses the that helping be we you patients by something of raise really are in these also so overall. may doing can And
next, financial what Geoff give really the bioequivalent of before the think is update, but at this So seen have mean XX probably terms Last just This additional giving minutes drug, day evidence I what helping the is subjects. patients in is this symptoms the has presented to I to I know word level improve have we the evidence, I over from and negative very just one least, of roluperidone to data of as minutes, is XX activities in we comments, I for study the And And the the is carry not end November. C order best overall a FDA pivotal next? think we received recently that started remarks obviously integrate meeting you Type of which study. an is explanation this over into magic bioequivalent tick I So just last boxes the at of when last out, the seen, exciting. to our which you have totality this functioning. this different of is from the
on is this data will we when will hand, in obviously have So data. report ongoing and we the this
also data, other and I'm activities the way referencing the data analyzing are needed the our soon here a -- as pre-NDA are we to to all integrated preparation NDA go right all be as all for meeting in as the continue are We together which putting different in points completed.
the to questions I financial stop I'm forward here update. hopefully looking And So give questions over for after all think interesting done update. your has I obviously, and Geoff, Geoff Geoff and I please. to his
